Defne Yarar

DeepBiome Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index3.0kcitations53works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(10), Cellular transport and secretion(10), Advanced Breast Cancer Therapies(10), Immunotherapy and Immune Responses(8), Lipid Membrane Structure and Behavior(7)

Publications53 total

1360 Controlled epigenetic upregulation of CXCL9 and CXCL10 in hepatocellular carcinoma promotes T-cell recruitment
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract 1726: Targeted epigenomic control of MYC as a strategy to treat EGFR inhibitor-resistant NSCLC
Cancer Research·2024
Abstract C104: Targeted epigenomic inhibition of MYC enhances responses to immune checkpoint and EGFR inhibitors in preclinical models of NSCLC
Molecular Cancer Therapeutics·2023· 1 cited
Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses.
Journal of Clinical Oncology·2023
Data from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental figure legends from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental table 1 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Data from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 1 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 1 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental table 2 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental table 1 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 2 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 4 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 2 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 3 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 4 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental Figure 3 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental table 2 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
Supplemental figure legends from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Johanna Lahdenranta(18), Gavin MacBeath(17), William Kubasek(15), Ulrik B. Nielsen(11), Sandra L. Schmid(9), Howard Bernstein(9), Armon Sharei(9), Scott Loughhead(8), Katarina Blagović(7), Ulrik B. Nielsen(7), Matthew G. Booty(5), Kelan A. Hlavaty(5), Katherine J. Seidl(5), Gaudenz Danuser(4), Clare M. Waterman(4), Carolyne K. Smith(4), Melissa Myint(4), Amritha Ramakrishnan(4), Dinah Loerke(3), Marcel Mettlen(3)